Immune-Related Adverse Events Clinical Trials

14 clinical trials for Immune-Related Adverse Events across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge — RECRUITING
• Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma — RECRUITING · NA
• Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors — RECRUITING
• Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients — RECRUITING
• Management of severe or rare immune-related adverse events in the context of an interdisciplinary tumor board — RECRUITING
• Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids — RECRUITING
• Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository — RECRUITING · PHASE1
• Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients — RECRUITING
• Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) — ACTIVE_NOT_RECRUITING · PHASE2
• Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events — NOT_YET_RECRUITING · PHASE1
• Study on Biomarkers of Immune-Related Adverse Events — NOT_YET_RECRUITING
• A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade — OTHER
• ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment — COMPLETED
• PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study — OTHER

Refine this search